Christopher S. Meldrum

Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience.

Golden Pine Ventures LLC is an Venture Capital firm founded in 2004. The firm is headquartered in Durham.

Pique Therapeutics, Inc. develops therapeutic vaccines for the treatment of cancer. It focused on the development of new therapies to treat non-small cell lung, pancreatic, colorectal, head and neck cancer. The company was founded by Eckhard R. Podack in 2005 and is headquartered in Durham, NC.

Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC.

Exigent Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. It focuses on the treatment and prevention of bacterial and infectious diseases. The firm seeks to discover and develop new pharmaceuticals to treat bacterial infections using its proprietary technology platform. The company was founded on May 23, 2007 and is headquartered in Durham, NC.

Cogenics Icoria, Inc. provides medical research services. The firm offers genomics and proteomics-related research instruments, consumables, data, including databases, software & other research-oriented products. Icoria offers gene expression analysis and other related services. Its tissue informatics software performs tissue analysis for toxicology studies of early-stage drug candidates and other purposes. The firm also provides biomarkers to develop diagnostics and therapies for liver injuries, metabolic conditions & cancer. The company is headquartered in Research Triangle Park, NC.

Arcato Laboratories, Inc. develops, produces and commercializes oral healthcare products. It offers OraWax, a wax-based proprietary formulation that has an over-the-counter anesthetic incorporated into its matrix so as to provide sustained relief from the discomfort. The company was founded on 2011 by Michael Jay and is headquartered in Durham, NC.

Avicenna Biosciences, Inc. is a biotechnology company that focuses on redesigning and optimizing drug candidates. The company is based in Durham, NC.